0001193125-13-396014.txt : 20131010 0001193125-13-396014.hdr.sgml : 20131010 20131010081005 ACCESSION NUMBER: 0001193125-13-396014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20131009 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20131010 DATE AS OF CHANGE: 20131010 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PERRIGO CO CENTRAL INDEX KEY: 0000820096 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 382799573 STATE OF INCORPORATION: MI FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-09689 FILM NUMBER: 131144634 BUSINESS ADDRESS: STREET 1: 515 EASTERN AVENUE CITY: ALLEGAN STATE: MI ZIP: 49010 BUSINESS PHONE: 2696738451 MAIL ADDRESS: STREET 1: 515 EASTERN AVENUE CITY: ALLEGAN STATE: MI ZIP: 49010 8-K 1 d611316d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 9, 2013

 

 

PERRIGO COMPANY

(Exact name of registrant as specified in its charter)

 

 

 

MICHIGAN   0-19725   38-2799573

(State of other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

515 Eastern Avenue, Allegan, Michigan   49010
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (269) 673-8451

Not Applicable

(Former name or address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 8.01. Other Events

On October 9, 2013, Perrigo Company (“Perrigo”) issued a press release announcing the record date and meeting date of its special meeting in connection with the proposed acquisition of Elan Corporation, plc (“Elan”) by Perrigo pursuant to the Transaction Agreement (the “Transaction Agreement”), dated as of July 28, 2013, between Elan, Perrigo, Leopard Company, Habsont Limited and Perrigo Company Limited (f/k/a Blisfont Limited) (“New Perrigo”). The special meeting of Perrigo is being held to seek shareholder adoption of the Transaction Agreement and approval of the merger and related matters.

Holders of Perrigo common stock of record as at 5:00 p.m. Eastern Standard Time on October 15, 2013 will be entitled to vote at the special meeting. The special meeting will be held on November 18, 2013 at 10:00 a.m. at Perrigo’s headquarters at 490 Eastern Avenue in Allegan, Michigan.

Perrigo will be mailing a definitive joint proxy statement/prospectus to its shareholders in the coming days.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits

 

99.1    Press release issued by Perrigo on October 9, 2013.

No Offer or Solicitation

This announcement is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Important Additional Information Has Been And will be Filed with the SEC

New Perrigo has filed with the SEC a registration statement on Form S-4 containing a joint proxy statement of Elan and Perrigo that also constitutes a prospectus of New Perrigo. The registration statement was declared effective by the SEC on October 9, 2013. In the coming days, each of Elan and Perrigo will mail to its stockholders or shareholders the joint proxy statement/prospectus. In addition, each of New Perrigo, Perrigo and Elan will file with the SEC other documents with respect to the proposed transaction. INVESTORS AND SECURITY HOLDERS OF PERRIGO AND ELAN ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain free copies of the registration statement and the joint proxy statement/prospectus and other documents filed with the SEC by New Perrigo, Perrigo and Elan through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by New Perrigo and Perrigo will be available free of charge on Perrigo’s internet website at www.perrigo.com or by contacting Perrigo’s Investor Relations Department at +1-269-686-1709. Copies of the documents filed with the SEC by Elan will be available free of charge on Elan’s internet website at www.elan.com or by contacting Elan’s Investor Relations Department at +1-800-252-3526.

Participants in the Solicitation

Perrigo, Elan, their respective directors and certain of their executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Elan is set forth in its Annual Report on Form 20-F for the fiscal year ended December 31, 2012, which was filed with the SEC on February 12, 2013, its Report on Form 6-K, which was filed with the SEC on February 28, 2013, its Report on Form 6-K, which was filed with the SEC on April 25, 2013 and its Report on Form 6-K, which was filed with the SEC on June 5, 2013. Information about the directors and executive officers of Perrigo is set forth in its Annual Report on Form 10-K for the fiscal year ended June 29, 2013, which was filed with the SEC on August 15, 2013, its Annual Report on Form 10-K/A for the fiscal year ended June 29, 2013, which was filed with the SEC on August 28, 2013, and its proxy statement for its 2012 annual meeting of stockholders, which was filed with the SEC on September 26, 2012. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the proxy statement/prospectus filed with the SEC and will be contained in other relevant materials to be filed with the SEC when they become available.

Cautionary Statement Regarding Forward-Looking Statements

This announcement includes certain ‘forward looking statements’ within the meaning of, and subject to the safe harbor created by, Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the business, strategy and plans of Perrigo, its expectations relating to the transactions contemplated by the Transaction Agreement and its future financial condition and performance, including estimated synergies. Statements that are not historical facts, including statements about Perrigo’s management’s beliefs and expectations, are forward looking statements. Words such as ‘believes’, ‘anticipates’, ‘estimates’, ‘expects’, ‘intends’, ‘aims’, ‘potential’, ‘will’, ‘would’, ‘could’, ‘considered’, ‘likely’, ‘estimate’ and variations of these words and similar future or conditional expressions are intended to identify forward looking statements but are not the exclusive means of identifying such statements.

Examples of such forward looking statements include, but are not limited to, statements about expected benefits and risks associated with the transactions contemplated by the Transaction Agreement, projections or expectations of profit attributable to shareholders, including estimated synergies, anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Perrigo, New Perrigo, Elan or the combined business following the transactions contemplated by the Transaction Agreement; statements about the future trends in tax or interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Perrigo, New Perrigo, Elan or the combined company following the transactions contemplated by the Transaction Agreement; statements concerning any future Irish, UK, US or other economic or regulatory environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological developments in the healthcare and lifesciences industry; and statements of assumptions underlying such statements.

While Perrigo believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Perrigo’s control. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur. Actual results may differ materially from Perrigo’s current expectations depending upon a number of factors affecting Perrigo’s business, New Perrigo’s business, Elan’s business and risks associated with acquisition transactions. These factors include, among others, the inherent uncertainty associated with financial projections; restructuring in connection with, and successful close of, the transactions contemplated by the Transaction Agreement; subsequent integration of the transactions contemplated by the Transaction Agreement and the ability to recognize the anticipated synergies and benefits of the transactions contemplated by the Transaction Agreement; the receipt of required regulatory approvals for the transactions contemplated by the Transaction Agreement (including the approval of antitrust authorities necessary to complete the transactions contemplated by the Transaction Agreement); access to available financing (including financing for the transactions contemplated by the Transaction Agreement) on a timely basis and on reasonable terms; the risks and uncertainties normally incident

to the pharmaceutical industry, including product liability claims and the availability of product liability insurance; market acceptance of and continued demand for Perrigo’s, New Perrigo’s and Elan’s products; changes in tax laws or interpretations that could increase Perrigo’s or the combined company’s consolidated tax liabilities; and such other risks and uncertainties detailed in Perrigo’s periodic public filings with the SEC, including but not limited to those discussed under “Risk Factors” in Perrigo’s Form 10-K for the fiscal year ended June 29, 2013, in Perrigo’s subsequent filings with the SEC and in other investor communications of Perrigo or New Perrigo from time to time.

The forward-looking statements in this announcement are made only as of the date hereof, and unless otherwise required by applicable securities laws, each of Perrigo and New Perrigo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

No Profit Forecast/Asset Valuation

No statement in this announcement is intended to constitute a profit forecast or asset valuation for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for either Perrigo, New Perrigo or Elan, as appropriate.

Dealing Disclosure Requirements

Persons interested in 1 per cent or more of any relevant securities in Elan or Perrigo may have disclosure obligations under rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2007 (as amended).

Irish Takeover Rules

The Perrigo directors accept responsibility for all the information contained in this announcement other than information relating to Elan, the directors of Elan and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the Perrigo directors (who have taken all reasonable care to ensure that such is the case), the information in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

Barclays, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Perrigo and no one else in connection with the matters described herein and will not be responsible to anyone other than Perrigo for providing the protections afforded to its clients or for providing advice in relation to the matters described in this announcement or any transaction or any other matters referred to herein.

General

The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this announcement and all other documents relating to the transaction are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such jurisdiction. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies involved in the proposed transaction disclaim any responsibility or liability for the violations of any such restrictions by any person.

Any response in relation to the transaction should be made only on the basis of the information contained in the joint proxy statement/prospectus or any document by which the transaction is made. Perrigo shareholders are advised to read carefully the formal documentation in relation to the proposed transaction once the joint proxy statement/prospectus has been dispatched.

SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

        PERRIGO COMPANY
    (Registrant)
    By:   /s/ Judy L. Brown
     

 

Dated: October 10, 2013       Judy L. Brown
      Executive Vice President and
      Chief Financial Officer
      (Principal Accounting and Financial Officer)

Exhibit Index

 

Exhibit 99.1 – Press Release dated October 9, 2013.

 EX-99.1 2 d611316dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

FOR IMMEDIATE RELEASE

PERRIGO COMPANY ANNOUNCES DATE OF SPECIAL SHAREHOLDER MEETING IN

CONNECTION WITH ACQUISITION OF ELAN CORPORATION, PLC

Allegan, Mich. – October 9, 2013 – Perrigo Company (NYSE, TASE: PRGO) today announced that it has that it has scheduled a shareholder meeting for Monday, November 18, 2013 in connection with Perrigo’s proposed previously announced acquisition of Elan Corporation, plc (NYSE:ELN) (“Elan”).

Perrigo’s special meeting of shareholders will be held on November 18, 2013 at 10:00 a.m. at Perrigo’s headquarters at 490 Eastern Avenue in Allegan, Michigan. The meeting is being held to seek shareholder adoption of the transaction agreement and approval of the merger and related matters.

Holders of Perrigo common stock of record as at 5.00 p.m. Eastern Standard Time on October 15, 2013 will be entitled to attend and vote at the meeting.

The Company expects to begin mailing a joint proxy statement/prospectus to its shareholders in the coming days. The joint proxy statement/prospectus will provide information for shareholders, as well as instructions for shareholders on how to vote their shares.

About Perrigo

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients (API). The Company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. The Company’s primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

No Offer or Solicitation

This announcement is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Important Additional Information Has Been and Will Be Filed with the SEC

A registration statement on Form S-4 has been filed with the SEC, which includes the joint proxy statement of Elan and Perrigo and that also constitutes a prospectus of Perrigo Company plc1 (“New Perrigo”). The registration statement was declared effective on October 9, 2013. Elan and Perrigo plan to mail to their respective stockholders or shareholders, as applicable, the definitive joint proxy statement/prospectus in connection with the transaction in the coming days. INVESTORS, STOCKHOLDERS AND SHAREHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT ELAN, PERRIGO, NEW PERRIGO, THE TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the registration statement and joint proxy statement/prospectus and other documents filed with the SEC by Elan, Perrigo and New Perrigo through the website maintained by the SEC at www.sec.gov. In addition, copies of the joint proxy statement/prospectus and other documents filed with the SEC by New Perrigo and Perrigo will be available free of charge on Perrigo’s internet website at www.perrigo.com or by contacting Perrigo’s Investor Relations Department at +1-269-686-1709 and copies of the joint proxy statement/prospectus and other documents filed with the SEC by Elan will be available free of charge on Elan’s internet website at www.elan.com or by contacting Elan’s Investor Relations Department at +1-800-252-3526.

Participants in the Solicitation

Perrigo, Elan, their respective directors and certain of their executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Elan is set forth in its Annual Report on Form 20-F for the fiscal year ended December 31, 2012, which was filed with the SEC on February 12, 2013, its Report on Form 6-K, which was filed with the SEC on February 28, 2013, its Report on Form 6-K, which was filed with the SEC on April 25, 2013 and its Report on Form 6-K, which was filed with the SEC on June 5, 2013. Information about the directors and executive officers of Perrigo is set forth in its Annual Report on Form 10-K for the fiscal year ended June 29, 2013, which was filed with the SEC on August 15, 2013, its Annual Report on Form 10-K/A for the fiscal year ended June

 

 

1 

Currently named Perrigo Company Limited but expected to be re-registered as Perrigo Company plc prior to the consummation of the transaction.

 

2

29, 2013, which was filed with the SEC on August 28, 2013, and its proxy statement for its 2012 annual meeting of stockholders, which was filed with the SEC on September 26, 2012. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the proxy statement/prospectus filed with the SEC and will be contained in other relevant materials to be filed with the SEC when they become available.

Cautionary Statement regarding Forward-Looking Statements

This announcement includes certain ‘forward looking statements’ within the meaning of, and subject to the safe harbor created by, Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the business, strategy and plans of Perrigo, its expectations relating to the transactions contemplated by the Transaction Agreement between, Elan, Perrigo, Leopard Company, Habsont Limited and New Perrigo, dated July 228, 2013 (the “Transaction Agreement”), and Perrigo’s future financial condition and performance, including estimated synergies. Statements that are not historical facts, including statements about Perrigo’s management’s beliefs and expectations, are forward looking statements. Words such as ‘believes’, ‘anticipates’, ‘estimates’, ‘expects’, ‘intends’, ‘aims’, ‘potential’, ‘will’, ‘would’, ‘could’, ‘considered’, ‘likely’, ‘estimate’ and variations of these words and similar future or conditional expressions are intended to identify forward looking statements but are not the exclusive means of identifying such statements.

Examples of such forward looking statements include, but are not limited to, statements about expected benefits and risks associated with the transactions contemplated by the Transaction Agreement, projections or expectations of profit attributable to shareholders, including estimated synergies, anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or rations; statements of plans, objectives or goals of Perrigo, New Perrigo, Elan or the combined business following the transactions contemplated by the Transaction Agreement; statements about the future trends in tax or interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Perrigo, New Perrigo, Elan or the combined company following the transactions contemplated by the Transaction Agreement; statements concerning any future Irish, UK, US or other economic or regulatory environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological developments in the healthcare and lifesciences industry; and statements of assumptions underlying such statements.

While Perrigo believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Perrigo’s control. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur. Actual results may differ materially from Perrigo’s current expectations depending upon a number of factors affecting Perrigo’s business, New Perrigo’s business, Elan’s business and risks associated with acquisition transactions. These factors include, among others, the inherent uncertainty associated with financial projections; restructuring in connection with, and

 

3

successful close of, the transactions contemplated by the Transaction Agreement; subsequent integration of the transactions contemplated by the Transaction Agreement and the ability to recognize the anticipated synergies and benefits of the transactions contemplated by the Transaction Agreement; the receipt of required regulatory approvals for the transactions contemplated by the Transaction Agreement (including the approval of antitrust authorities necessary to complete the transactions contemplated by the Transaction Agreement); access to available financing (including financing for the transactions contemplated by the Transaction Agreement) on a timely basis and on reasonable terms; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance; market acceptance of and continued demand for Perrigo’s, New Perrigo’s and Elan’s products; changes in tax laws or interpretations that could increase Perrigo’s or the combined company’s consolidated tax liabilities; and such other risks and uncertainties detailed in Perrigo’s periodic public filings with the SEC, including but not limited to those discussed under “Risk Factors” in Perrigo’s Form 10-K for the fiscal year ended June 29, 2013, in Perrigo’s subsequent filings with the SEC and in other investor communications of Perrigo from time to time.

The forward looking statements in this announcement are made only as of the date hereof, and unless otherwise required by applicable securities laws, Perrigo disclaims any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

No Profit Forecast/Asset Valuation

No statement in this announcement is intended to constitute a profit forecast or asset valuation for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for either Perrigo, New Perrigo or Elan, as appropriate.

Irish Takeover Rules

The directors of Perrigo accept responsibility for the information contained in this communication, other than information relating to Elan, the directors of Elan and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the directors of Perrigo (who have taken all reasonable care to ensure such is the case), the information contained in this communication is in accordance with the facts and does not omit anything likely to affect the import of such information.

Persons interested in 1 per cent or more of any relevant securities in Elan or Perrigo may have disclosure obligations under rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2007 (as amended).

 

4

General

The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this announcement and all other documents relating to the transaction are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such jurisdiction. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies involved in the proposed transaction disclaim any responsibility or liability for the violations of any such restrictions by any person.

Any response in relation to the transaction should be made only on the basis of the information contained in the joint proxy statement/prospectus or any document by which the transaction is made. Perrigo shareholders are advised to read carefully the formal documentation in relation to the proposed transaction once the joint proxy statement/prospectus has been dispatched.

Arthur J. Shannon, Vice President, Investor Relations and Global Communications

(269) 686-1709

E-mail: ajshannon@perrigo.com

Bradley Joseph, Senior Manager, Investor Relations and Global Communications

(269) 686-3373

E-mail: bradley.joseph@perrigo.com

 

5

GRAPHIC 3 g611316g31q75.jpg GRAPHIC begin 644 g611316g31q75.jpg M_]C_X``02D9)1@`!`@$!+`$L``#_X0V+17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L```` M`0```2P````!061O8F4@4&AO=&]S:&]P(#7U5F9VAI:FML;6YO8W1U=G=X>7 MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_ MV@`,`P$``A$#$0`_`!]=OZA?]<[*LK$^FVVVMYCM7NL?6YW\EZR.J%K?\8#W.(:UO4*2YQ,` M`"F2YQ7?]3^N/U>Z?COM^V59-@'LHQWML>YW[OZ,NV?U[%HY)Y(C",<1+BA& MQP\5M''&$CE,Y$5+3U53S_U(^N>;FYC>D]5<+7V-)QLDC:\N8-SZ;VMACG;/ MH/VL^A[UW:\C^J0]7KS^M93A3A]/-F7F70=C76;_`$Z6_P#"/?;[*_IK?/U] MZ]U*^QOU?Z4;J:HW&P.>Z#]`V>F^JNES_P#1^I:F#3U2B]ZDN/^K_U]^VYXZ7U?&^Q9CW>FQPD--G^@LKM_2T6_N?3] M11Z]]>-UKMK?W&_15?[MEX^#A]5<6^\?!F]_ M'P\=Z7P_5[),N,P/KEUSJW6<:GIW3PSI5]I;]JN989K9+KK!:PLH8_8S]&S] M)^D53%_QG6-OR!GXK&U5-?Z0I+B]]C7;*JO?[6->WZ3T?NF74``D"R`==4?> M,>A)H$T#3VO4NH8W3,"_/RB11CL+W[1+CX-8/WGN]K5F_5GZU8GUA;<*JGX] MV.1ZE5D'VNGTWM>SV_FK#H^L_7\W`ZO=U3I=56#BXI>*+J[6&QUGT*W.N_G: MO1;9ZNRO_1(W^+S.PK\?/&-@T].KI=67FMSGETA^MMEY<_;7L]B<<'#BR&4; ME$Q]49#ACQ=$#+>2`!J,@?21ZC3V22X:[Z^]4ZAU(X'U9P&Y<3MLMGW-:=KK MMNZEM%.[Z+[K/_(*KG?7_P"L_3+CB]1Z;11D@;H=O`+3IO86V6,L9N_/9:@. M4RFAH)$7PF0XZ_NI/,XQKK5UQ`>FWT).N9P.M]:P,#-ZI];*Z\.EA8,6BK:7 M&0[?%^K_`,9)SP%7=RVC7K^Q[Y)<+@_XQKZ,PX?U@P3AO:0++&!P M-YG+.$,(C( MQO&+HM3!CA*60RB#4NKP/^,9E'3ND].Z5A4MHQ;+G/+*QM;^B;(W1]+<^S>J M?U;ZO]:L#I%-/2^BMR<5Q=8W)]TV%SCN>[:?^M_];73_`%YZ%D=9Z0W[(W?E MXC_5K9P7B"VVII/YSF_17+?5/Z[U=#Q7=)ZI3;Z=#W>D6-'J5ESBZRF^FPUO M]MA?_+_,3L1X^6J,1EE&5SB=_P"\B8X<]F1A$QJ)&S3Z]@?6WK&=^TG]'LQL MEK&@>B.75G?5;+G;O4:H_7";OK9^G9!M;B^K6>VYK-["NOJ_QC=$R,O'P\6K M(MNR;64LEK6-!>X,W/+G[_;.[^;7)_79[!]=G@N`.[%[^35)AGD,Q&>/V^&$ MN'R]/[RS-&/`3&7'Q3CQ/JK&,K8UE;0QC`&M:T0`!HUK0%Y1]2*JK?K?4+&! MX8;WM#A,.;NVO_K-7K"\I^H;V'ZX,`<"8R.#_65;EOYKF/[H_P"Z9N8'ZS#_ M`'GO_K?_`.)CJ?\`X7?^1RYF[_I+JOK@0/JO MU,DP/L[]5P7U:^U6?5;ZQMP9=>6TZ5ZN+/?ZP;M_X'U$[`+Y:8NKG`7V]449 MM,\#5U"?Y,?JG]8,7ZK=2R\?J$64W!M3[J"+`'4E^QU?^DIM]5WT43ZS]5=] M+A882@<8A+*!&[X:]7]UR?\8YLQG=*Z9O+JL3&+@3^<\;:/4=_*:RO_ M`,$7:_57#HP_J]@5T@`/I9<\]R^T"VQSO[3US_UKP*?K9TC'ZST)PRK,7>UU M0T>YAV^M3L=[FY-+F,>RI_T_^N5JG]5_K[B=-P&=+ZPRUK\6:Z[6MD[!]&J^ MLD6UV5?S?T%#*,LG+QC$7/'(^Y#]*_[K+$QAGE*1],XC@E^C]K=_QH8..[IV M)U#:!D57"C=W=78U[BQW[VU[-[%>_P`7.19?]6JV6:_9;K*:R=3L!#VC^SZF MQM?!-=%-33[-[_^,7H/U;Z..B]' MQ^G[@^Q@+KGCAUCSOM+?Y.X[6?R$,P,.6ACG\_%Q"/6,4X_7GE./R5PD_O2? M_]'MLKJ;/MMM>%T._-R:GP;S57367M_.;E9)9O\`^,8I#*^N=XFO`PL.>U^0 M^TCXC'I#?_!%NI*3C`KT#SEQ%8(W?J/^#0<`T_7E^IRNFU^3:;G?]7[\38Y=4DC'+*_3&/TB@P%>J1^I>3HP/KGT]Q=B8?1= M>10RRDG^TH7=0^ME;_5R_JSCY3M)LIN8YVG'TV/>NO23O=-^K'$G_#C+_FR1 MP"M)FO\`!IY$_7W(QA/4>@Y^*T?2<&[V_P"=^C38GU]^I?J;P/L=OB^C:[7Z M7NJ:]=>LWJ?_`#=@_M7['Y_:?3G_`,%2$\1N\FU_\`@_46=G-_Q4.>0]U;'_O8WVB/_98.I65=TO\`Q=V2<3K.10X] MG5/>T?)V,Q__`((GX_NXD#<^$&S&4>*)_P`59D]ZB*A9&X-'_G/2_4GZO]!M MZ'3F654Y^3DC?D66M;9L?)_5PVW=Z?H_0?\`Z7^<1_K7TSZJX?1,E^1B8V-8 M6.&,ZMC*[3;'Z(4^F&O=[]O_`*,7$U]'Z^'AG&7]UA]RL?",4=JOBB8^;V/ M^*W'R68>?DV-(Q[[*VU$Z!SJVN;>]G[WTJZ]_P#P2Z_*Z9TW+=OR\6C(%LVJO?TW()_7^K-8._ MJLSG?@_$K324<41[9E$=28\+ZD[J'U=Z2PU^OB83 M1S6US&?^!LA6>G=1P^IXK7!E@!`.TECOIAKOI-7E>'T?ZG2#F=?+ MO%E&+8T_*RZN[_STO2/JO7TFOHE#.C6/NP6E_IV6;@XG>[U=WJLJ=_.;O\&J M^:.*(],Y3G>MCA'XL^*60_-$1CTHV__9_^T27%!H;W1O.$))30/S```````)```````````!`#A" M24T$"@```````0``.$))32<0```````*``$``````````3A"24T#]0`````` M2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!: M````!@```````0`U`````0`M````!@```````3A"24T#^```````<```____ M_________________________P/H`````/__________________________ M__\#Z`````#_____________________________`^@`````____________ M_________________P/H```X0DE-!`@``````!`````!```"0````D`````` M.$))300>```````$`````#A"24T$&@`````#BP````8``````````````#$` M``")````*P!0`&4`<@!R`&D`9P!O`%\`4`!R`&4`7!E`````$YO;F4````)=&]P3W5T M/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1 M``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S M)&+A7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`" M$0,1`#\`'UV_J%_UQRL&G-OH;?ELI9MML#6;VU-GTV/'M]WYJULWZE?6W#J= MD8/5[LJRL3Z;;;:WF.U>ZQ];G?R7K(ZH6M_Q@/RC'>VQ[G?N_HR[9_7L6CDGDB,(QQ$N*$;'#Q6T<<82 M.4SD14M/55//_4CZYYN;F-Z3U5PM?8TG&R2-KRY@W/IO:V&.=L^@_:SZ'O7= MKR/ZI#U>O/ZUE.%.'T\V9>9=!V-=9O\`3I;_`,(]]OLK^FM\_7WKW4K[&_5_ MI1NIJC<;`Y[H/T#9Z;ZJZ7/_`-'ZEJ9S/+7D/M@1``,]>&$9%?@SU`<9)))X M-/5*+WJ2X_ZO_7W[;GCI?5\;[%F/=Z;'"0TV?Z"RNW]+1;^Y]/U%'KWUYRND M?6!W33CU.Q6>D;+B7;PUXW6NVM_<;]%5_NV7CX.'U5Q;[Q\&;W\?#QWI?#]7 MLDRXS`^N77.K=9QJ>G=/#.E7VEOVJYEAFMDNNL%K"RAC]C/T;/TGZ15,7_&= M8V_(&?BL;54U_I"DN+WV-=LJJ]_M8U[?I/1^Z9=0`"0+(!UU1]XQZ$F@30-/ M:]2ZAC=,P+\_*)%&.PO?M$N/@U@_>>[VM6;]6?K5B?6%MPJJ?CW8Y'J560?: MZ?3>U[/;^:L.CZS]?S<#J]W5.EU58.+BEXHNKM8;'6?0K:W.>72'ZVV7ES]M>SV)QP<.+(91N43'U1D.&/ M%T0,MY(`&HR!])'J-/9)+AKOK[U3J'4C@?5G`;EQ.VRV?QU--;G?Z/>]-'+3-UP\, M=Y\7ZO\`QDG/`5=W+:->O['ODEPN#_C&OHS#A_6#!.&]I`LL8'`USJUUN/9N ML]/;[]]=CUU=W5JJ[Z:F--K+PTMM806P_P#FW-_?WH3P9($"0WU!_1/U3'-" M0-';0CJ__]"OUS'KROKQD8MT^E?FUU6;3!VO%+7;2NTJ_P`6_P!6JWASFW6M M'YCK2&_^!BMW_27&]3>W_P`<)PW"?VC3I/\`Q*];5[F( M+;:FD_G.;]%I67.+K*;Z;#6_VV%_\O\Q. MQ'CY:HQ&6497.)W_`+R)CASV9&$3&HD;-/KV!];>L9W[2?T>S&R6L:!Z(Y=6 M=]5LN=N]1JC]<)N^MGZ=D&UN+ZM9[;FLWL*Z^K_&-T3(R\?#Q:LBV[)M92R6 MM8T%[@S<\N?O]L[OYM"X`[L7OY-4F&>0S$9X_;X82X?+T_O+,T M8\!,9T.$PY MN[:_^LU>L+RGZAO8?K@P!P)C(X/]95N6_FN8_NC_`+IFY@?K,/\`>>_^M_\` MXF.I_P#A=_Y%RG^+C'^U=.ZUB[MGKM97N\-[+F;O^DNJ^N!`^J_4R3`^SOU7 M!?5K[59]5OK&W!EUY;3I7JXL]_K!NW_@?43L`OEIBZNF>M<7%WVEC6.16RH?]%MS5/D$XY3DCAE*8TX[]!_1XN%AA M*!QB$LH$;OAKU?W7)_QCFS&=TKIF\NJQ,8N!/YSQMH]1W\IK*_\`P1=K]5<. MC#^KV!72``^EESSW+[0+;'._M/7/_6O`I^MG2,?K/0G#*LQ=[75#1[F';ZU. MQWN;DTN8Q[*G_3_ZY6J?U7^ON)TW`9TOK#+6OQ9KKM:V3L'T:KZR1;795_-_ M04,HRR4I'TSB."7Z/VMW_&A@X[NG8G4-H&15<* M-W=U=C7N+'?O;7LWL5[_`!^PC9ZU\$UT4U-/LWO_XQ>@_5OHXZ+T?'Z?N#[&`N MN>.'6/.^TM_D[CM9_(0S`PY:&.?S\7$(]8Q3C]>>4X_)7"3^])__T>VRNIL^ MVVUX70[\W)J?!O-5=-9>W\YN5DEF_P#XQBD,KZYWB:\#"PY[7Y#[2/B,>D-_ M\$6ZDI.,"O0/.7$5@C=^H_X-!P#3]>7ZG*Z;7Y-IN=_U=S54RNB?6G*<'Y+N MCY;AP;\1[OQ-CEU22,ZIKUUZS> MI_\`-V#^U?L?G]I].?\`P5(3Q&[QRCWX)?\`?<2C'(/TP>W%%#7]:?JQF,+/ MVACO8_0LL<&R/-EVU9/UPZU1T[H1=T.REEN5:VEUV,6;F-(<]SV^E^?M9Z;7 M_P"#]19VOFR[N&8N4QW]HXS;%3S.G$7_K?5*'7 M_P##MS`^/^O89&<9?W6'W*Q\(Q1VJ^*)CYO8_XK5X?1_J=(.9U\N\648MC3\K M+J[O_/2](^J]?2:^B4,Z-8^[!:7^G99N#B=[O5W>JRIW\YN_P:KYHXHCTSE. M=ZV.$?BSXI9#\T1&/2C;_]D`.$))300A``````!5`````0$````/`$$`9`!O M`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@` M;P!T`&\`&%P+69I;'1E#IX87!M971A('AM;&YS M.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAA<'1K/2=835`@=&]O;&MI="`R+C@N M,BTS,RP@9G)A;65W;W)K(#$N-2<^"CQR9&8Z4D1&('AM;&YS.G)D9CTG:'1T M<#HO+W=W=RYW,RYO&UL M;G,Z:5@])VAT='`Z+R]N&UL;G,Z>&%P34T])VAT='`Z+R]N&%P+S$N,"]M;2\G/@H@(#QX87!-33I$;V-U;65N=$E$/F%D;V)E M.F1O8VED.G!H;W1O`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P` M@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P M`/8`^P$!`0&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"((( ME@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ M"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4, MC@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2 M#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1 M;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G M%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT7 M01=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW M&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''LP> M%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'. M(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<`^(#Y@ M/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$ M1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW M2GU*Q$L,2U-+FDOB3"I,%W)7AI> M;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/662 M9>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM M8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%] MH7X!?F)^PG\C?X1_Y8!'@*B!"H%K@%JX8. MAG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/ M-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A, MF+B9))F0F?R::)K5FT*;KYP0)ZNGQV?BY_ZH&F@V*%'H;:B M)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OI MK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V M>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#L MP6?!X\)?PMO#6,/4Q%'$SL5+QHM\IWZ_@-N"]X43AS.)3XMOC M8^/KY'/D_.6$Y@WFENV<[BCNM.]` M[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3% MQL?(R'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E) M66EYB9FINT&S\MI[-\N[U?\`+UK/)'9322,T4;2/X*B@2.J#4J#@I\J^75B^^_Y'/\U?K_``=5NOK# MYQ5/86Y<-%+74NW,=V]W/LK.Y!Z93,M/A,CEZVIPS9"8J%C2IGI86<@-(HY] MQEMOW@?9WQ'NAMT#7>U< M[FXNT%0@EGC8T'!6)X^F1GI'_P`MW^=-\HNF_D)M_P"*WSJS.6WCM#*[X'66 M8W7V)2?9]J]/;RFKEP-)%N++1)$V?V]39I5@KDK8Y:N!9//'4,BF-S'W4]A. M4-\Y8N.N+VN+_TOS[WUNH]>O7']1_M_>JC&>/7 MNNM2_@@_ZW/U_P!;\>_&F1UJN2//JL+^83_-6Z!_EUUW7FW^S-O[XWUO/L:" MKR^.VGL*FQ+5N+VGCJM:"MW-E:S.9'%T$5.]:6AI8$=YJB6)Q9%4O[EGVP]G M.9/=`;G<;9<06^WVITF62I#2$5$:A034"A8\%!!/'J+/<7W7V+VY?;8-QM9K MB]N!J$<94:4!H78MCB"`.)H>%">CW=*=P;$^0'5&P>Z>LLI)F=A=E;;Q^Z=L M9">EDH:J7'9!"?#6TO<./7?OW7NO7']??NO=>N/?CCCUX$'@>O>]5'KU[K__ MT`5_F2_]OD^Y?_%G>K?^M/77OIU[5_\`B/\`MO\`TJ[O_#/USC]QL>]NZD\/ MWC'_`($Z^@)VAWWTKTQMC.;Q[3[3V+L7;NW*2JJ\OD-P[EQ5"U-'2*7FABHY M*G[VLKCITQT\,.;IT!.+1,)A)@NN]R?*CLW; M=;)M?,U>W,L,)L:DW%CA]I58?&9JEQ.Y,OO+*T=1"Z5"XZB:F6165:AF5@N' M_)'W;N8N9-LCYCYGW2+9]GD`D`2HI&JY`H+)"_T]B+? M/NLS3[=+N?(G-MON:+\,;:07IQTRHQC!]`P`/FPZ(]H^\E'#N$>WKFS-V;IV/@MNP;7W; M18.CR^+WU0Y+)8W<=#GI<7FJ>>C6FQX(00W?R#U+8^X4]O?;/<>>N<[CDNYN MSMU_#%,S^)&6*M"0"I4,IJ2:5K0?/J7^=_<*QY0Y2@YMMH%OK"9XPFA](99` MS!@U&\APIQP:=5:Y3_A2IT'3=!X7L&@Z6W/D>\MS;DW#AL9T-2;NI:Q3W,,7W4^9/ZPS[?/S%`G+T M42,UTR:2SO7]**(N69@`*L6514<3CJ)Y?O+;'^XA?V^RR/OKR,JVX;4JJH4B M2230*5J1I52<9(&>E#G?Y].Y^M?B!T)\I^T?B2Z)\A.P^T=I[0VMMOM0TJQ; M;ZWCQ4:[MJ*W-;'>21,YDZRI@B@2,@1TOE\A$@145M]W6TWCGKF;D[9.<`$V MNW@DDDDA+=\U:I1'4#1137@=5.EUQ[[WVU6DG(ITE^X?^%*'2.TNK>LQ>X-[[0AW9O'K^3=JX_;'433 MS542X/<6\Z?;M1-N//)'3K-)3T=#%%%!*ADFC<^/VOV7[JF_W6\;K!O>]QVN MQ03F..71^ISVVT[;/LVT&ZWF6,.\>L^'! M4_"SA07;U`4`5SG'15_YI/RS^,_:W5'P7[+^;7PFWEE>RNWNGLOVMMU>K^]) M-DY39FS<_0Q[197H@;>6MQVCD;< M.>^39)-UN[0S*(;@Q&-&?",3&Y8,.[(!6I`.3UL#=2_)#XV]!_R[^I/D3D6FA78,= M/9';NS]JF6JR^6?.YW(9N'%)J>*MRF+V5LC<6-VY+44Z%UADK:I[?2]C[G8_ M=GY>Y?MK?^O/N9:V5],O8@"(NJF0&E8&0`X)`7[!U#/_``0W,&]7%Q_4[V_F MN[*(Y8^(S4^8B0A2?($G[3TC8_\`A3?GV/]*U M1654^Y7D:F3$T^#HNL#N&IK%JAH-,(4J"P*V!]JC]T^T@A?<[[W%MQLJIXC2 M"'`CXZM;2Z`*9U4H./2'_@G+V:5-NM.1W.\EM'AF1B==::0HC#5KBG&O5MG0 MW\P#>NVOAGNGY:?S&=B8_P")8HM]9O&8+8LV&W)3YVLVJE-B8MIQ8_`9J:JW M)N#.0D6EPY6@TJ$;O9V.K]A:@7 MJK/>'_"E2NW/N;)X;XP_"3L/M/$8UV;^,Y[.Y./+ST4>IONZK:.Q=H[O?#1S MQH63S5[&PY%[@3#9_=;LMMM(;CGCW!MK&1P044*`&'D))775]H05\NHHNOO( M7VXWA1HE9.(T'4R2-3-`RD^0)-.CKEG[R&P7MX-LYGV MR7;+DMIUUUQ*:T[P0&0`X)HP'$T`)%Y'8_R,ZYZR?:0R]3D)XFD$B+J'!6^/.V\M;GN7UG@1I&UNVEE MD)1M5:$4I@@X.JE#U.FX\R;9MQM#/(SI.NI2@#KII@U\PW$4K7RZ$C_2'M#_ M`)W"?^1@"21.9J%ZD2H`RG4@L1]??4;V:NEL? M8_E^]:(2+#87#E3P8(\S:36HH:4X=?S/WEG*4SFHJI8NLZ"3,U#.^N9TK\QO'*I%/-6_<+B.I:3O7=%;393LZ&H[&RM# MM^N7#YB"DHJ;:>-BP[54J08N&E#5`220R.BL`MRCSSS-[U^ZG*FV1=2YUDL%!9ZFF!3H2\[OL,UWN#J%A9 M`I\(&I<@MP9L"HX"H\ST8W^:U_-%^/W\Q7JK9^$VU\7.SM@=P[%W;29/;_9> MY1MBK9-I5%+74VY-I5D^$,N5JJ#)2RT]1#$UX8JBG#@`EKA'V7]I.:_;#?+R MYO>;+"?8KF`K)#&\AJX(,;@,%4%<@GCI)'0J]V_<_EKW&V6TM[3EN[BWF"4% M)G"80@AT)7)!P0.`(KTD).W=U;[_`)!&?ZWW0]?*.COF_L7:^U'KUJ1+3[-W M-MK-[NH,8GW(#?;X[.9/(K$JV6.%D0`!1[-#LEA8?>3LMRL](6_V"9Y-)4ZI M481DFG`LBQUKQ-3GB2X;O=W_`-W^^VV]9BUEO$:KJK_9O&[@5/HVO`X`CJVW M_A-?\;NELM\>^SOD)G=@[>W+VQ6=LY?K^CW1N/%4.9J=O;4P.W=MU\6-VVM? M3SKAFR-9FYGK)H0LU2%1&;0BK[A;[UO-._IS5MG*\6XR1[*MFDQC1BH:1V<% MGH1JTA!I!J%R1QZEO[L_+.R25GF-M;U9B23WR#)/''"OH.DGWI8H8-CY0CA MB5(UFGH%`4"HB)H!@>?ET=W^0M\8>B]O_`#K?M>+K?:N5[%[FGWID]_;OS^$ MQN:S63I\7O+/[9QN!IZO(4U1)0[9Y)7#2.3[C3[PO-W,.X> MY.\[1-N5-BM.0-KW--NA;<+U M6:61T5F8:V`2I!H@I\/#S.>JE_\`A4+34]%W;\3J.CIX*2CI>FM\TM)2TL,< M%/34\&[<9%!3T\$2I%#!#$@5$4!54```#W./W0W9]EYT>1RSF[B))-224-37 MU/GU#WWIE5-ZY21%`1;5P`!2@$F!]@\NC`_S!^H.U^T?Y$'PFS'6V/R^=P_5 MFT.FM^]DX#"PU-75R[.@Z\R&(;<,M!3*[UE!M;(Y**HJ>&\$#-.0%B9E#OMM MONR[+]XSGN'=FC2>\N+F&!WH`)#*#HU'AX@!4>IHOF.A!S_LV[;M["\D2[8C MO#:P023*MD>U-G[NWI MF]\G>E92[<;?\6;S%7E<'NW'9>9$AW#]IMZ6GQC0^1JFG-"%">-HRQ7]XGVV M]P=ZY^EWO:]JN=QVF>&-8O"!?P2BA7C*BNBKAI`1VMKK754`P]AO<'D79>2$ MV?<]T@L=UBFD:7Q2$\74Q*.&_$0E$TUU#3PH0>J=N^M[;=^;7\ZO;^[OA/2U MTE%NGN_IVHV_NO;N*K,/_$60 M!I;&;^6]ON_;WV"NK3W`D`:.PN=43E31)@_A6W$ZF.H*`/A)T^74.\P7EOSS M[V07?)$9T27MOIE52M6CT:YQP(`*ER3Q`U>?0U_\*2N^]X[Q^9F#Z*ER-6FP M.E.M=LYG&;?6HF7&U6\]_P!+4YK+;AJJ4/X):]<*:.CBD*EHHD<*1K:Y!]U/ MENPL>1KWF/P0;^^NI$+T&H10T`133X=19R/,D>G1Y]Y??KR\YSL]@,S#;[2! M"%!-/$E[F_$CXG]0]<[&PN,IMS MW.Z=D6=XXD)JL42N515'`8`+4XM4DGK+;V]Y6V[E+E+9]OVZW19&@1Y7TT:2 M1E!9FIDT)H*G```ZHT_X4H_$+KI.JM@_,/:NWL1M_L/&[\QO7/9.2Q='3T,N M^,#NBAR$N!K\X*>*-8V@\L^X*[CL[-;Q;G: MK-(JDA3,I*.U!2A("DD9U,Q\ST)/N\;H.9>1VL-UC6:3;K@Q1LPJ1&X#A?L# M:@!PT@#R'6Q+]I2_\J\'_4J/_HWWC1J?_?C?MZR*\*/_`'V/V=?_T@6_F2`? M\/)]S?7_`+*=ZL_WF'KH?[;CWTX]K"1]W_;33_EEW?\`AGZYQ^XO_3[]T'_2 M1B_P1]?1@_(/^O[YC<#7KHWYCJM[^;9\<,]\I?@-WOUGL[$U&=WU0X?&[_V- MAJ1==7EMS;!RM+N2#$T<7UGK4?;^0 M)8+,8Y&/!4E1H]1^2E@Q^0/4=>['+USS/R!S#M-E'KO3&KHHXLT;J^D?TF4% M1\SUJT?R$OG;TY\3^TNUND?D;68K9.R^Y9\#6X;>^ZZ2*##[/["VBN2QDV'W M?55L=]OX_-T%:8ON9@L--64JI,4$FM[--PH()^/^\8_/K,B3F?D6*'ZB7?=J$/KXT'^> MO5,7\^/L[JKN3^5;@>RNEMQ[?W?U[N/Y%=>IAMT[8CTX3-/AIM^8+(S4,_V] M,*R"#)8Z:$2J"C^,E&9;$SO]W7:-XV3WE;:>8+62#<(]MGU1R&CKJ$;*#4XJ MI!IQSU#?OON.T;S[3KN.QS1R[?+?)I>,=K%1*A(H!6C*17Y=*/\`X31N)_UR;$D9.UP\/\`3S=*?NS8Y!OJ\/WA)Q_YIQ=% MQ_X5*@'K?X<I%?I;?S`_')Z]!G[U( M)V;E.@)_7F_X[%U:3_(T_P"W7OQC_/\`D'8/T_\`$I;T]PI[[?\`3V><_P#G MH7_JU'U+GLH*>V/*W_-%O^KC]41_\*C?^9[?%8V-O]$&_OI_AO#'?[>_O)'[ MH5&V/G#T-U%_U;/6/OWJ!7?.4QJ`/TS_`/5SH,_YG_R;[@V)_+R_ED_''9>> MS&U>O.S_`(O[?WKV#48.KJTO*>R;E[H^[7,]_;I-N5GNC1PAP"(];.3*`1AL`!N*BM./15[G MV_M?R]9S-%M]WMB/+0D:RJJ`A(XJ.)'F2M>'1F^A_C5_PG#KNJMDUN M[>[\'N'=-7M_$56Y*WLCMW?&R]U)G)J&"7+4F0VSCI-MX_%?;UQD010P,BJ+ M+)(/6P1YAYK^]''O.XPVFP2)9K*RH(;:.6/0"=.F0AV<$9J6J:Y`X="?E_EG M[N+[182WF_HUVT8+F:XDB?505K&-*KGT!'SZMY^'78_\F7H:M&Q_B3V?\5]H M;EW,T&/FJJ+?&+DWONF268"FQE1N_>.1GW%F!)4,/%1BK9-9&B,&WN#N=MG] M].8$;<.UBS1HV\.//$1H-*@#STX'$]3'RANOLOLD@LN4]UVJ*YD[21 M(OB/Z#6YJ:^E<^G5#G_"D_XF;WP/?>T_E[A\5D,IUCV3LO;O7V[\W14SS4>T M=][4^\H\-%EYX@ZT=)NC;]1"*.672CU%))&#J*@Y&_=1YUL)M@O>1[N4)NEM M<--$I(K)%)3Q*#U1@=0'!2#U`WWE^4KV+?+'G*WB,FV3Q)'(P!TI*F%U$5HK M+ITDX)!%?6]7^6)_,_\`CS\DOC%UI1[T[7Z\Z\[JV%M'$[,[&V+O+=N$VKDI MLEM;'P8I=V8&'.9"D.7V[N*CI$JUEIS)]O)(\4NEDYQX]V/:/FGE7FW=#8;- MV/NERYS'RQMPOMWMK;=H(EB MECED5#J10-:ZB`RN*&HX&HZI<_X4)_S&NH^Z\'LGXC=$[QPW8F-V[NZG[`[7 MWIM3)4V:VHF8Q=%68[:^S,-F*!YZ#-U]/-DIJNMDII)8H66&*YD,@2??NR>U M^\[!)N?/',EDUJTD)AMXY%*R!=0,DCJU&0&@500"1J/``F$_O$>XVU;Y%8\G M\OW2W(2;Q)GC8,A;20B*14-2I+$&E:`9KU;U_(6^).[/B[\)J;,=BXBMV_V! MWYNRI[6RFWLG3ST>3V_MN7&4&$V5C,K15,44U)DY\-0&NEC87C%:J,`RL/<& M_>*YSLNP3IA5O1Z<+!KAC+E^;'U> MY^Y-]TO=L:$@#J"N;/;KVMCW^?F MOF7>#;;G),)3JGB4:EI\*%"Y&!49/H1CHSM9_.$^!LE0]'LKLG>W;U8C%!#T MYTAW-V-!+("5\<&4P&QI\+,21P5J2I_K["T7LK[@T#;CMUM8@Y'U5U;05'J` M\H:GY="5_>+D1F*6&XSWK#C]-;7$O\UCI^P],%5_-:P-63_<[X/_`,Q'>L%Q MXJS'_&/*X>DG'X:([BSV,J])'(+0KP?;R^T5W$?]V?.?+]L!ZWJ2']D8;_#T MR_NM:N*V/)^^SKZBT9/^KA7JGCY=]9?#GY6[SRW9N^/Y4/\`-"ZU[`S>J;/[ MSZBZHPFUY=PUS$ELON#;LV;S.W,KE9"?W:DTB5,]KO(S<^YQY&W[GCD^S@VG M:?>#EBZL$%$BN99'"#%%1M*,%'DNHJ*G'4-\W[9R;S;=S[G?>UW,EO?29>2" M*--9K\3*2ZECYL%#'S/1%L/\4OY6^R*]*KMGXV?SB:>CA=6FI-P=.[=PN/"* MP8BMK-O4,5YBDE:ZR22*YJ".CA?`;Y;?R9?B=UK7]/?'+Y=; M?Q^U\_N_([UJH>V]P;EH,HN=RE!B\=5!=!UQE, MYFMJ)U-WGM'&5C5>YJ+'T.0.02BJ,I/5Q-!C8O&I1"C7^M[>POR=S'[F>T4V MZ7>V>M?BKTALCHGJ%LU)UWLB'*IMV3<&:&X1 MW!5O59=8*9:L-7Y24H0@"QV7\7]Q_P`T\Q;ES;O^X\P[P4_>-RX:30I5:A0N M%J:8`XD]#CEK8=NY9V6QV3:=1V^!2$+,&-"2QJ0`.)\@!T67YL_RO?B[\_-T M;'W=W]'V*^7Z^P&5VUM\[*WFVUZ48W,9"')UGWU.,97BJJ/NH5T/==*\6]B[ MD+WA44!'>M,?(]!CG7VPY8Y^N;*ZWX3^+;H43 MPW5<$UR&1O/[.M?K^=UO3J[#4?Q<_E,=#]3T>_\`L38-!UQB-H;WW375U9O+ M8+[F>AVWL?9>`RD0Q\%;E]Y8Z.&7+5%3Y:1:5H3X?-9XLD_N_P!EN]Q)SE[S MTVR;6)[V%8 M521R3)$&HJ1JPH"7%"Y/:!I[?,&4ZX_X3#=!ILC;O^EGOSMG(=BOCH9=V3;' MAVIB=IQ9:91)4T6"I,O@\ODWH:%V,233S>2?1Y"D>K0H8WC[V_-+[E=G8N7[ M%-IUD1"8.\FGR+E9$6IXT`Q6E32O0EVG[KO+R[?;?OK?+MMSTCQ/"T",'T74 MC,0.%2<\:#AT0[^:3_(TZF^%/QFROR+ZD[FWKGUVEN#;&'W#M#L>GV[*S_WAM]Y\YL@Y6W_`&2W M3ZB-RDMN'&G0"Q5U=G!5@"*AEH:<:]`/W5]B]EY)Y9EYCV7>9V\&1`\\L.;* MY>"&X_2)0I,VH,RZ::-6G45'$DD\>IF]BKN;FSVS%AS%&+JU29X`)1J#Q`*P M4UXZ=5`>(``\@>FCM#_A.!_+_P!\YFJS.T:SN/J@5E5+4O@MI[RH,OMRF69R M[P8RAW?@\[D*"`7(5%JV1%L`HM[4[9]Z;W-L+=+>Z%C>$8URPD/^9C=%/"IJ MM2?/IKWUY.\UI+>VFK)5)%9>-<:T9O^-$#TZ,#\7OY'OP(^+6[,+V#A MMC[B[1WYMZ6*KP>?[>SL6ZJ/"Y.%@\65Q.UZ3'8C:U-7T[C5#+)232PMZD8, M`P#7.'W@/0 M[C#8R76X(:J\[!P#ZZ%54J/(LK$>1ZM[6X)!-^/]X]PDHH2*Y_9_+J8`34@_ ME]G7/W?K?7__U-T^/X/?$(=E[I[DK/CIU1G.TMYY>;.[CWUNK:>/W?N&MRDX M025,%;NA,NV+2T:Z8J000I8:5'L6_P!?.)!?5I^Q:#Y=&8Q>'Q.#I( MZ#"XO'8BAB%HJ+%T5-CZ2,`6`CIZ2**%``/P!["\UQ/D=N3KOK_>,;Q;NV M+L[=44@L\6X]L83.1N/Z.F3H:I6'^N/:ZWW3<[.GTFXSQ4X:)'6G^\D=(+C: M]LNU*W6W02J?)XT8?S!Z*)O[^6+_`"^>S9YJK>/Q"Z-K*RH+&:MQ.RD_SZ(IV-_P`)W/Y'>WMK?0>D\"D_D4\/]I! MZ!.Y?=\]O+XL]M;W5I)Y>%*2`?6D@?\`D1T5C-_\)]>Z^OW^]^,'\R+NW8\\ M#ZZ'%[I;<])3P!#JAC.5V3O+&)I6P%_X>?\`@OL:0_>3V#=52/G#VKV^Z4#+ M+H8D^NB2,@?[UT$+C[O^_P"W'5RM[CWD'HK&10/M,3Y^W2.D%EOA)_PHFZFU M3=?_`#>PW;M)2&]/1U'9;U^0J8HQZ5DINV.OX:8,UK%37-_P;V8P^X'W9-Y- M=T]NY+*4\=,0`'S'@2C^8Z+[CDC[P^U@_NWGA+J->%9F9C^4\9_P]5'?*'X: M?SE]Z=X1_)#N/X_=I9[N+'-M.>#L7J_%;2R\\%;L&.FAVOF::#K6OKJ:FR>- M%#$RS+`C2-&&()]S?R?S][$V&P_U5V3F"VAV:025@F,@!$E2ZDRBE&J>+D>G M4.\U MZ_B+1[HR]#`*<[IWAT_VOL+)5+0QA#4Y.GPJP8.>H)75(\,5.C->RK[C:\^[ MY[-[W=1R[!STMO&[5\-+BWFXFNE:DN/E4L?MZ'UI[Z>[&T6[Q;WR@9I$6FMX M)8B,<6^%2?L`'50OSD_F3_+CYTUU#1=ZYX;?V'@J\9'"=3[0PV0VSLG&Y*-9 MX8LM74M=)59//YN"&=T2HKIYO"&(B6.[7G3V\]J.1_;Y9)^7K;Q=Q=2&N)&5 MY2#^!3@*E0"0H!/F3U#7/7N;SESTPAWR8Q[>I!6",:(JC%2*DEJ<"Q-#P`X= M'[^-W\_O='Q.Z0V3T'T;\1.I,+M+9%`U/!/EM\[PRF3SV9K96K,[N7.24M%C MFK,UGLG+)43L"`"X10$55$9KN2_N&K00Q`*H^%%[R`J M+VC%<9R3U(W+GWA+GE39+'8=FY+MH[6%:5,LAU,$C_`^T,7W8_:S M:HC)O?,5T4499IHH5'V]IQ^8Z5R?>*]R-S<)L^RVP8^2Q/(?RJW'\CTP0][? M\*(/EM4>/:E#\D-N8K*C0)-H]?8?HK;D4,@(NNY,OC=N5--$5_M??:R/R?:I MN7ONQXC&"\K73M3U1&="?M4#[.DJ;Y]XKF]Y/I(]QBADQ18Q;* MOV.5C-/]L>MFC^49\>ODW\;OBQD-G_+;,U6;[?W)VKO#?=94Y'?=5V)E8,-G MJ#;U-CJ/*;BJ*BLC:NBEQDQ:&&>:&(,-+7)`Q,]Y>9N4^:.;8;SDNU$.Q16: M0JHB$*ZD9R=*#RHPS05ZRA]I>7^9N7.69;/FV]^Z]U[W[KW7O?NO=>]^Z]U[W[KW70^GOW M6APZ\?H?]?\`XD>]]5/`_;UT/^*_[W[;3S^WJP\NNQ]?=$^,]6\NHM?_`,`J MK_EA)_T*?:RV_MX?],.DMY_N--]G^7JL;O?_`(&U?^^_+>Y1V[_0_M/48[IP MN/M'14<7_P`7"F_Y;?\`$^SK_0C^?1$OX?M/^'JTWX[?\6]?^69_Z%'N/^8? H[+\QU(.P?VJ_:?\`!T:7V#NAD>!ZXC\?ZWO7XCUI>`^SKE[WU;K_V3\_ ` end